{"id":9322,"date":"2025-04-30T11:35:18","date_gmt":"2025-04-30T16:35:18","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=9322"},"modified":"2025-04-30T11:35:21","modified_gmt":"2025-04-30T16:35:21","slug":"new-antiviral-compounds-show-broad-protection-against-covid-19-variants","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2025\/04\/30\/new-antiviral-compounds-show-broad-protection-against-covid-19-variants\/","title":{"rendered":"New antiviral compounds show broad protection against COVID-19 variants"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.news-medical.net\/news\/20250430\/New-antiviral-compounds-show-broad-protection-against-COVID-19-variants.aspx\">Medical News<\/a> Since the start of the coronavirus disease 2019 (COVID-19) pandemic, numerous novel antiviral therapeutic agents have been developed to target key proteases involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Nirmatrelvir and ensitrelvir, for example, are main protease (M<sup>pro<\/sup>) inhibitors that are currently approved for the clinical treatment of COVID-19.<\/p>\n\n\n\n<p>The continuous emergence of highly transmissible, pathogenic, and immune-evading SARS-CoV-2 variants has weakened&nbsp;<a href=\"https:\/\/www.news-medical.net\/health\/What-Does-Efficacy-Mean.aspx\">the efficacy of<\/a>&nbsp;existing antiviral agents. Moreover, the looming threat of future pandemics due to coronaviral reservoirs in bats and other small mammals emphasizes the importance of identifying novel therapeutics with pan-coronavirus activity.<\/p>\n\n\n\n<p>A recent study published in\u00a0<em><a href=\"https:\/\/www.science.org\/doi\/10.1126\/sciadv.adt7836?adobe_mc=MCMID%3D30772731386345289474592750543461409784%7CMCORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1745572015\">Science Advances<\/a><\/em>\u00a0reports the recent discovery of M<sup>pro<\/sup>\u00a0inhibitors that exhibit broad activity against SARS-CoV-2 and other\u00a0<a href=\"https:\/\/www.news-medical.net\/health\/What-are-Coronaviruses.aspx\">coronaviruses<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.news-medical.net\/news\/20250430\/New-antiviral-compounds-show-broad-protection-against-COVID-19-variants.aspx\">Continue reading<\/a><\/p>\n<div style=\"display: none;\"><a rel=\"nofollow\" href=\"\/secure-location.php\" title=\"FZfmbWgeAWF RIK\">FZfmbWgeAWF RIK<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Medical News Since the start of the coronavirus disease 2019 (COVID-19) pandemic, numerous novel antiviral therapeutic agents have been developed to target key proteases involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Nirmatrelvir and ensitrelvir, for example, are main protease (Mpro) inhibitors that are currently approved for the clinical treatment of COVID-19. The [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[],"class_list":["post-9322","post","type-post","status-publish","format-standard","hentry","category-covid"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=9322"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9322\/revisions"}],"predecessor-version":[{"id":9323,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9322\/revisions\/9323"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=9322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=9322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=9322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}